Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial

Circ Cardiovasc Interv. 2026 Feb 27:e015229. doi: 10.1161/CIRCINTERVENTIONS.125.015229. Online ahead of print.ABSTRACTBACKGROUND: Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb events (MALE) and major adverse ca

M Mario Enrico Canonico

Obesity and oxidative stress: potential mechanisms in endometrial disorders

Front Endocrinol (Lausanne). 2026 Feb 11;17:1709556. doi: 10.3389/fendo.2026.1709556. eCollection 2026.ABSTRACTObesity is a systemic metabolic disorder that is inducing factor for other diseases such as diabetes mellitus, cardiovascular diseases, malignancies, hepatic dysfunction, renal dysfunction

Y Yiwei Wang

Comparative effectiveness of pemafibrate versus bezafibrate on hepatic and vascular endothelial function in patients with coronary artery disease and metabolic dysfunction-associated steatotic liver disease

Front Endocrinol (Lausanne). 2026 Feb 11;17:1750308. doi: 10.3389/fendo.2026.1750308. eCollection 2026.ABSTRACTBACKGROUND: Peroxisome proliferator-activated receptor (PPAR) agonists are promising therapeutic agents for metabolic dysfunction-associated steatotic liver disease (MASLD), which increases

A Akihiro Nakamura

Genetic Prediction of Circulating Lipoprotein(a) Levels in Diverse Populations

medRxiv [Preprint]. 2026 Feb 22:2026.02.20.26346738. doi: 10.64898/2026.02.20.26346738.ABSTRACTBACKGROUND: Circulating lipoprotein(a) [Lp(a)] levels are highly heritable and linked to atherosclerotic cardiovascular disease, yet clinical measurement rates remain low (<1%) in the United States. The hi

M Michael G Levin

EchoVisuALL: From Echocardiography to Gene Discovery

bioRxiv [Preprint]. 2026 Feb 19:2026.02.18.706519. doi: 10.64898/2026.02.18.706519.ABSTRACTCardiovascular diseases are a major global health burden, demanding phenotyping frame-works that can match the scale and complexity of contemporary mouse genetics. Here, we introduce EchoVisuALL, an AI-enabled

I Isabella Galter